Introduction: These analyses examine (a) survival from the start of renal replacement therapy (RRT), based on the total incident UK RRT population reported to the UK Renal Registry, including the 18% who started on PD and the 6% who received a pre-emptive transplant and (b) survival of prevalent patients. Changes in survival between 1997 and 2008 are also reported. Methods: Survival was calculated for both incident and prevalent patients on RRT and compared between the UK countries after adjustment for age. Survival of incident patients (starting RRT during 2008) was calculated both from the start of RRT and amongst the cohort who survived at least 90 days after RRT, both with and without censoring at transplantation. Both Kaplan-Meier and Cox adjusted models were used to calculate survival. Causes of death were analysed for both groups. Relative risk of death was calculated compared with the general UK population. Results: The 2008 unadjusted 1 year after 90 day survival for patients starting RRT was 87.3%. In incident patients aged 18-64, the unadjusted 1 year survival had risen from 85.9% in 1997 to 91.9% in 2008 and for those aged 565 it had risen from 64.2% to 75.8%. The age-adjusted one year survival (adjusted to age 60) of prevalent dialysis patients rose from 85% in 2000 to 89% in 2009. Diabetic prevalent patient one year survival rose from 76.6% in 2000 to 83.6% in 2009. The age-standardised mortality ratio for prevalent RRT patients compared with the general population was 19 at age 30 years and 2.4 at age 85 years. In the prevalent RRT dialysis population, cardiovascular disease accounted for 24% of deaths, infection 19% and treatment withdrawal 14%; 22% were recorded as uncertain. Treatment withdrawal was a more frequent cause of death in patients aged 565 at start of RRT than in younger patients. The median life years remaining for a 25-29 year old on RRT was 20 years and 4 years for a 75þ year old. Conclusions: Survival of patients starting RRT, has improved in the 2008 incident cohort. The relative risk of death on RRT compared with the general population has fallen since 2001. Death rates on dialysis in the UK remained lower than when compared with a similar aged population on dialysis in the USA. 
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Introduction
The analyses presented in this chapter examine (a) survival from the start of renal replacement therapy (RRT); (b) the survival amongst all prevalent RRT patients alive on 1st January 2009 and (c) projected life years remaining for RRT patients. They encompass the outcomes from the total incident UK dialysis population reported to the UK Renal Registry (UKRR), including the 18% who started on peritoneal dialysis and the 6% who received a pre-emptive renal transplant. These results are therefore a true reflection of the outcomes in the whole UK RRT population and are not distorted by focusing solely on the haemodialysis cohort. Additionally, analyses of the 1st year UK survival data include patients who were recorded as having started RRT for established renal failure (as opposed to acute kidney injury) but who had died within the first 90 days of starting RRT, a group excluded from most other countries' registry data.
The term established renal failure (ERF) used throughout this chapter is synonymous with the terms end stage renal failure (ESRF) and end stage renal disease (ESRD) which are in more widespread international usage. Within the UK, patient groups have disliked the term 'end stage'; the term ERF was endorsed by the English National Service Framework for Renal Services, published in 2004.
The prevalent patient group was defined as all patients over 18 years old who had been on RRT for at least 90 days at one of the UK adult renal centres and who were alive on 31st December 2009. This included incident patients in 2009 and patients who had been on treatment for longer but excluded patients who had stopped treatment before this date.
Since 2006, the UK has openly reported and published centre-attributable RRT survival and remains the only country doing so. It is again stressed that these are raw data which continue to require very cautious interpretation. The Registry can adjust for the effects of the different age distributions of patients in different centres and the proportion of patients with diabetes, but lacks sufficient data from many participating centres to enable adjustment for other comorbidities and ethnic origin, which have been shown to have an impact on outcome (for instance, better survival is expected in centres with a higher proportion of Black and South Asian patients). This lack of information on case mix makes interpretation of any apparent difference in survival between centres difficult, although age and comorbidity, especially diabetes, are the major factors associated with survival [1, 2] . Despite the uncertainty about any apparent differences in outcome for centres which appear to be outliers, the UKRR will follow the clinical governance procedures as set out in chapter 2 of the 2009 UKRR report [3] .
Methods
The unadjusted survival probabilities (with 95% confidence intervals) were calculated using the Kaplan-Meier method, in which the probability of surviving more than a given time can be estimated for members of a cohort of patients, without any adjustment for age or other factors that affect the chances of survival in the cohort. Where centres are small, or the survival probabilities are greater than 90%, the confidence intervals are only approximate.
In order to estimate the difference in survival of different subgroups of patients within the cohort, a stratified proportional hazards model (Cox) was used where appropriate. The results from the Cox model were interpreted using a hazard ratio. When comparing two groups, the hazard ratio is the ratio of the estimated hazards for group A relative to group B, where the hazard is the risk of dying at time t given that the individual has survived until this time. The underlying assumption of a proportional hazards model is that this ratio remains constant throughout the period under consideration. Whenever used, the proportional hazards model was tested for validity.
To allow comparisons between centres with differing age distributions, survival analyses were statistically adjusted for age and reported as survival adjusted to age 60. This gives an estimate of what the survival would have been if all patients in that centre had been aged 60 at the start of RRT. This age was chosen because it was approximately the average age of patients starting RRT 14 years ago at the start of the Registry's data collection. For the last 7 years the average age of patients commencing RRT in the UK has been stable around an age of 65 years, but the Registry has maintained age adjustment to 60 years for comparability with all previous years' analyses. All analyses were undertaken using SAS vs. 9.2.
Definition of the date renal replacement therapy started
The incident survival figures quoted in this chapter are from the first day of renal replacement therapy whether with dialysis or a pre-emptive transplant.
In the UKRR all patients starting RRT for ERF are included from the date of the first RRT treatment wherever it took place (a date currently defined by the clinician) if the clinician considered the renal failure irreversible; should a patient recover renal function within 90 days they were then excluded. These UK data therefore include some patients who developed acute irreversible renal failure in the context of an acute illness for instance and were recorded by the clinician as being in irreversible established renal failure. Capture of data on these patients requires accurate coding. Previously, the Registry asked clinicians to re-enter a code for established renal failure in patients initially coded as having acute renal failure, once it had become clear that there was no recovery of kidney function. However, adherence to this requirement was very variable, with some clinicians entering a code for established renal failure only once a decision had been made to plan for long-term RRT [4] . All UK nephrologists have now been asked to record the date of the first haemodialysis session and to record whether the patient was considered to have acute kidney injury (acute renal failure) or to be in ERF at the time of the first session. For patients initially categorised as 'acute' , but who were subsequently categorised as ERF, the UKRR will extract information from the first session of RRTonwards if available and will assign the date of this first session as the date of start of RRT.
Recent UKRR analyses of electronic data extracted for the immediate month prior to the start date of RRT provided by clinicians highlighted additional inconsistencies in the definition of this first date when patients started on peritoneal dialysis, with the date of start reported to the Registry being later than the actual date of start. These findings are described in detail in chapter 13 of the 2009 Report [4] . This concern is unlikely to be unique to the UK, but will be common to analyses from all renal centres and registries.
In addition to this varying clinical definition of day 0, there is international variability on when patient data are collected by national registries with some countries (often for financial reimbursement or administrative reasons) defining the 90th day after starting RRT as day 0 or others collecting data only on those who have survived 90 days and reporting as zero the number of patients dying within the first 90 days. Some other countries do not include initial urgent/emergency dialysis in intensive care units or acute wards.
Thus as many other national registries do not include reports on patients who do not survive the first 90 days, survival from 90 days onwards is also reported to allow international comparisons. This distinction is important, as there is a much higher death rate in the first 90 days, which would distort any such comparisons.
Methodology for incident patient survival
Patients are considered 'incident' at the time of their first RRT, thus patients re-starting dialysis after a failed transplant were not included.
The incident survival cohort was NOT censored at the time of transplantation and therefore included the 6% who received a pre-emptive transplant. Censoring would exclude this healthier patient cohort. An additional reason for not censoring was to facilitate comparison between centres. Centres with a high proportion of patients of South Asian and Black origin are likely to have a healthier dialysis population, because South Asian and Black patients are less likely to undergo early transplantation.
The incident ('take-on') population in any specific year excludes those who recovered within 90 days from the start of RRT, but includes patients who recovered from ERF after 90 days. Patients newly transferred into a centre who were already on RRT were excluded from the incident population for that centre and were counted at the centre at which they started RRT.
Some patients recover renal function after more than 90 days but subsequently returned to RRT. If recovery was for less than 90 days, the start of renal replacement therapy was calculated from the date of the first episode and the recovery period ignored.
If recovery was for 90 days or more the length of time on RRT was calculated from the day on which the patient restarted RRT.
The one year incident survival is for patients who started RRT in 2008 and was calculated for 1 full year through 2008 and 2009 (e.g. patients starting RRT on 1st December 2008 were followed through to 30th November 2009). The 2009 incident patients could not be analysed as they had not been followed for a sufficient length of time.
For analysis of 1 year after 90 day survival, patients who started RRT in October through December 2008 were not included in the cohort, as 1st quarter 2010 data on these patients were not yet available.
To help identify any centre differences in survival from the small centres (where confidence intervals are large), an analysis of 1 year after 90 day survival using a rolling 4 year combined incident cohort from 2005 to 2008 was also undertaken. For those centres which had joined the UKRR in the previous 1-3 years, the available data were included.
The death rate per 1,000 patient years was calculated by counting the number of deaths and dividing by the person years exposed. This included all patients, including those who died within the first 3 months of therapy. The person years at risk were calculated by adding up, for each patient, the number of days at risk (until they died or were lost to follow-up) and dividing by 365.
Adjustment of 1 year after 90 day survival for the effect of comorbidity was undertaken using a rolling 5 year combined incident cohort from 2004 to 2008. Eleven centres had returned >85% of comorbidity data for patients in the combined cohort. Adjustment was first performed to a mean age of 60 years, then to the average distribution of primary diagnosis for all the eleven centres. The individual centre data were then further adjusted for average distribution of comorbidity present at these centres.
The survival hazard function was calculated as the probability of dying in a short time interval considering survival to that interval.
Methodology for prevalent patient survival
For dialysis patients, all who had been established on RRT for at least 90 days on 1st January 2009 were included in these analyses.
For calculating the survival of transplant patients, those who had been established with a transplant for at least 6 months were included.
As discussed in previous reports, comparison of survival of prevalent dialysis patients between centres is complex. Survival of prevalent dialysis patients can be studied with or without censoring at transplantation. When a patient is censored at transplantation, the patient is considered as alive up to the point of transplantation, but the patient's status post-transplant is not considered. This censoring could cause apparent differences in survival between those renal centres with a high transplant rate and those with a low transplant rate, especially in younger patients where the transplant rate is highest. Censoring at transplantation systematically removes younger fitter patients from the survival data. The differences are likely to be small due to the relatively small proportion of patients being transplanted in a given year compared to the whole dialysis population (about 14% of the dialysis population aged under 65 and 1% of the population aged 65 years and over). Only the censored for transplantation results have been quoted throughout the prevalent analyses.
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Methodology of causes of death The ERA-EDTA registry codes for causes of death were used. These have been grouped into the following categories:
Some centres had high completeness of data returns to the UKRR regarding cause of death, whilst others returned no information.
Adult patients aged 18 years and over, from England, Wales, Scotland and Northern Ireland, were included in the analyses of cause of death. The incident patient analysis included all patients starting RRT in the years [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] . Previously data analysis was limited to centres with a high rate of return for cause of death. When this was compared with an analysis of all the cause of death data on the database, the percentages in corresponding ERA-EDTA categories remained unchanged so the latter data were therefore included.
Analysis of prevalent patients included all those aged over 18 years and receiving RRT on 1 January 2009. The death rate was calculated for the UK general population (data from the Office of National Statistics) [5] by age band and compared with the same age band for prevalent patients on RRT on 1st January 2009.
Methodology of median life expectancy (life table calculations)
Kaplan Meier survival analyses were used to calculate the hazard of death by age group (18-34, 35-44, 45-54, 55-64, 65-74, 75þ ) for incident patients starting RRT from 1997 to 2008. The patient cohort inclusion criteria are the same to that of the incident cohort described above. Patients were then followed until death, censoring or end of the study period.
This analysis showed that the hazard of death stabilized after year one with variability increasing again after nine years. Due to this, the average hazard of death for the periods 1 to 9 years was calculated for each age group. Life expectancy was calculated as (1 -hazard of death) which gives the probability of surviving until the next time period. Median life years remaining is then the difference between the age when reaching the 50% probability of survival and the age of starting RRT.
Methodology for comparing mortality in prevalent RRT patients with the mortality in the general population Data on the UK population in mid-2008 and the number of deaths in 2008 were obtained from the Office of National Statistics for each nation separately and added together [5] . The age-specific UK death rate was calculated as the number of UK deaths/UK population. The age-specific 'expected' rate of deaths in the RRT population was then calculated: years exposed for RRT patients Â UK death rate/1,000. The age-specific observed number of RRT deaths was calculated as the actual number of deaths observed in 2009 and the RRT death rate as the actual number of deaths in 2009/years exposed for RRT patients Â 1,000. The observed/expected ratio was then calculated.
Results of incident (new RRT) patient survival
The 2008 cohort included 6,767 patients who started RRT, without any periods of renal function recovery lasting more than 90 days.
It is hard to set survival standards at present because these should be age, gender and comorbidity adjusted and this is not yet possible from UKRR data. The current 5th Edition of the Clinical Practice Guidelines [6] does not set any standards for audit of patient survival.
The 3rd Renal Standards document defined standard primary renal disease using the ERA-EDTA diagnosis codes (including only codes 0-49); this excluded patients with renal disease due to diabetes and other systemic diseases. It is more widespread practice to simply exclude patients with diabetes, so these analyses are also included in this report to allow comparison with reports from other registries. The results are shown in table 6.1. The trend of improving patient survival continued with improvement seen in both those patients with 'standard primary renal disease' and those with all other primary renal diseases (excluding diabetes). For a longer term comparison, the 2002 cohort is also shown.
Comparison of survival between UK countries
Two years' incident data have been combined to increase the size of the patient cohort, so that any differences between the 4 UK countries are more likely to be reliably identified (table 6.2). These data have not been adjusted for differences in primary renal diagnosis, ethnicity, socio-economic status or comorbidity, nor for differences in life expectancy in the general populations of the four countries. There was a significant difference in 90 day survival between the UK countries (p ¼ 0.03) and the 1 year after 90 day survival was once again significantly different (p < 0.0002) between countries. It is postulated that greater prevalence of cardiovascular disease in Wales and Scotland compared with England may account for these differences.
Modality
It is impossible to obtain truly valid comparisons of survival of patients starting on different modalities, as modality selection is not random. In the UK patients starting peritoneal dialysis as a group were younger and fitter than those starting haemodialysis, and were transplanted more quickly. The age-adjusted one year survival estimates on HD and PD were 88.1% and 93.8% respectively which both show a trend in improvement in survival from 2002 (figure 6.1 and table 6.3). Results from the USRDS and Australasian (ANZDATA) registries, after adjustment for comorbidity, are similar.
Age Tables 6.4 to 6.9 show survival of all patients and those aged 65 and above and those aged below 65 years, for up to twelve years after initiation of renal replacement therapy. In the UK, short term survival remained similar There was a curvilinear increase in death rate per 1,000 patient years with age, shown in figure 6.3 for the period one year after 90 days. There were no significant differences between the UK countries.
The effect of censoring age related survival at the time of transplantation
The KM long term survival curves published in all reports prior to the previous 3 years were censored at the time of transplantation. This was not made clear in the description of methodology and was misleading as it made the longer term outcomes of younger patients (who are more likely to have undergone transplantation) appear worse than was actually the case. This is because only those younger patients remaining on dialysis (who may have more comorbidity than those transplanted) will have been included in the censored survival analysis. Without censoring, the 10 year survival for patients aged 18-34 years is 81.3% (figure 6.4), which contrasts with a 56.4% survival if censoring at the time of transplantation (data not shown). For more detailed information on this effect, refer to the 2008 Report chapter 7 Survival [7] .
From figure 6.4, it can be seen that 50% of patients starting RRT aged 50 survived for 10.5 years, 50% of patients starting aged 60 survived for 5 years and 50% of patients starting aged 70 survived for 3 years. Figure 6 .5 shows the survival of incident patients, excluding those who died within the first 90 days and shows that 50% of patients aged 60 survived for 5.5 years and 50% of patients aged 70 survived for 3.5 years.
Age and hazard of death by age in the first 12 months Figure 6 .6 shows the monthly hazard of death from the 1st day of starting RRT by age, which falls sharply during the first 3-4 months particularly for older patients. In renal registries that receive details on all patients starting RRT from day zero, this difference in the change in hazard of death between the age groups will affect proportionality in any Cox model analysis that uses data starting from day zero and combines these different aged cohorts. This is why survival from day 90 is often used by other countries. Both are presented here to demonstrate this phenomenon of early deaths.
The hazard of death for each 10 year increase in patient age (unadjusted for primary renal disease) is shown in table 6.6. The difference in the hazard of death in the first 90 days and in the year after day 90 has been increasing over time (data not shown). This could reflect greater access to RRT for older and possibly more comorbid patients in recent years.
Changes in survival from 1997-2008
The 1st year death rate per 1,000 patient years is shown in figure 6.7. There was a continued fall in death rate in the 65 years and over age group to 265 It is important to note that these death rates are not directly comparable with those produced by the USRDS Registry, as the UK data include the first 90 day period when the death rates are higher than subsequent time periods.
The unadjusted KM survival analyses (tables 6.7 and 6.8, figures 6.8 and 6.9) and annual death rates show a large improvement in 1 to 12 year survival across the time periods for both those under and those aged 65 years and over. One year survival amongst patients aged less than 65 years at start of RRT has improved from 85.9% in 1997 to 91.9% in 2008.
Change in survival on renal replacement therapy by vintage RRT patients in the UK continued to show no evidence of a worsening prognosis with time on RRT (vintage). Figure 6 .10 demonstrates this clearly for all patients. In the older age groups, there were decreasing numbers remaining alive beyond 7 years accounting for the increased variability seen. Figures 6.11 and 6.12 show these data for the non-diabetic and diabetic patients respectively.
Time trend changes in incident patient survival, 1999-2008 The time trend changes are shown in figure 6.13. The left hand plot, which includes only those centres that have been sending data continuously since 1999, shows a similar improvement in survival to the plot in which data from all renal centres is analysed. Analysis of centre variability in 1 year after 90 days survival The one year after 90 day survival for the 2008 incident cohort is shown in figure 6 .14 for each renal centre. The tables for these data and for 90 day survival are given in appendix 1 at the end of this chapter (tables 6.24 and 6.25). The age-adjusted individual centre survival for each of the last 10 years can also be found in appendix 1, table 6.26.
In the analysis of 2008 survival data, some of the smaller centres had wide confidence intervals (figure 6.14). This was addressed by including a larger cohort across several years, which will also assess sustained performance. Similar to previous years, this is shown as a rolling 4 year cohort, with the data in this report for the 4 year period 2005 to 2008. These data are presented as a funnel plot in figure 6.15. For any size of incident cohort (x-axis) one can identify whether any given survival rate (y-axis) falls within plus or minus 2 standard deviations (SDs) from the national mean (solid lines, 95% limits) or 3 SDs (dotted lines, 99.9% limits). Table 6 .10 allows centres to be identified on this graph by finding the number of patients treated by the centre and then looking up this number on the x-axis. These data have not been adjusted for any patient related factor except age (i.e. not comorbidity, primary renal disease or ethnicity) and have not been censored at transplantation, so the effect of differing centre rates of transplantation was not taken into account.
There are known regional differences in the life expectancy of the general population within the UK [8] . Table 6 .11 shows differences in life expectancy between the UK countries. These differences in life expectancy are not accounted for in these analyses and are likely to be one of the reasons behind the variation in survival between renal centres [9] .
Analysis of the impact of adjustment for comorbidity on the 1 year after 90 day survival Comorbidity returns to the UKRR have remained poor. Using the combined incident cohort from 2004-2008, it was found that 11 centres had returned comorbidity data for more than 85% of patients and these centres were included in this analysis. Adjustment was first performed to age 60, then to the average distribution of primary diagnoses for all 11 centres. Further adjustment was then made to the average distribution of comorbidities present at those centres.
It can be seen that adjustment for age has the largest effect, with only minor differences within centres after adjustment for primary renal diagnosis; in two centres (Bradford, Swansea) adjustment for comorbidity had a noticeable effect on adjusted survival (table 6.12 and figure 6.16). Table 6 .14 gives the 2009 one-year death rate for prevalent dialysis patients in each UK country. The median age of prevalent patients in Northern Ireland and Wales was higher than those in England and this together with socio-economic reasons probably explains the higher death rate in these two countries. Table 6 .15 gives the 2009 one-year survival for transplanted patients. Figure 6 .17 shows the one year survival of dialysis patients who were alive and receiving dialysis on 1st January 2009. One year survival of prevalent dialysis patients by centre The age-adjusted one year survival of dialysis patients in each centre is shown in table 6.13 and is illustrated in figures 6.18 and 6.19; the data for those patients aged <65 years and those aged 65 years and over are separated. Figure 6 .20 shows the age adjusted data (60 years) and in figure 6.21 as a funnel plot. The solid lines show the 2 standard deviation limits (95% limits) and the dotted lines the limits for 3 standard deviations (99.9% limits). With over 70 centres included, it would be expected by chance that 3 centres would fall outside the 95% (1 in 20) confidence limits. Table 6 .13 allows centres to be identified by finding the number of patients treated by the centre and then looking up this number on the x-axis.
Results of prevalent patient survival analyses
The 2009, one year death rate in prevalent dialysis patients by age band The death rates on dialysis by age band are shown in figure 6.22. The younger patients included in this analysis are a selected higher risk group, as the similar aged transplanted patients have been excluded. The increase in death rate is non-linear with age: with a 10 year increase in age in the younger patients, the death rate increased by about 20 per 1,000 patient years compared with an increase of 100 per 1,000 patient years in the older age groups. In all age groups these death rates are lower than comparable death rates reported by the USRDS in 2009 [10] . The previously improving age-adjusted survival in patients with diabetic renal disease in the UK has plateaued over the last three years (table 6.16) with no further improvements in survival. Death rate on RRT compared with the UK general population The death rate compared to the general population is shown in table 6.17. Figure 6 .24 shows that the relative risk of death on RRT decreased with age from 19 times that of the general population at age 30 to 34 to 2.4 times the general population at age 85þ. With the reduction in rates of death on RRT over the last 10 years the age-standardised mortality ratios compared with the general population are falling (7.7 in 2001, 6.3 in 2009) .
Results of analyses on causes of death

Data completeness
Data completeness is shown in table 6.18. Overall, it was less than 50% and has not improved over the last 5 years. Interpretation of patterns of cause of death must be cautious as it was not known whether non-return was associated with cause. Some centres consistently achieve a very high rate of data return for cause of death because a process is in place to make sure that these data were entered. The Scottish centres overall had the highest rate of data return. Several centres have shown significant improvement in data returns but others that were reporting these data in previous years appear to have discontinued collection.
Causes of death in incident RRT patients
Causes of death within the first 90 days See table 6.19.
Causes of death within one year after 90 days
Treatment withdrawal as a cause of death (table 6.19  and table 6 .20) was more common in the older age group.
Causes of death in prevalent RRT patients in 2009  Table 6 .21 and figures 6.25 and 6.26 show the frequency of the causes of death for both prevalent dialysis and transplant patients. These data are neither age-adjusted nor adjusted for differences in the comorbidity between the two groups. Cardiac disease as a cause of death was less common in the transplanted patients as these were a pre-selected low risk group of patients. Malignancy and infection were both responsible for a greater percentage of deaths in the transplanted group. Treatment withdrawal still occurs in the transplanted group, in patients who choose not to restart dialysis when their renal transplant fails. Table 6 .22 shows there were no differences in the causes of death between transplanted patients aged <55 or 555 years. Table 6 .23 shows these data for dialysis patients. Dialysis patients aged 65 years and over were significantly more likely to withdraw from treatment than younger patients but otherwise causes of death were similar in both age groups. For the statistical methodology for this analysis please refer to the methodology section at the start of this chapter. Figure 6 .27 shows the median remaining life years expected by age band. All incident patients starting RRT from 1997 to 2008 have been included in this analysis and the projected median survival will be different for low risk (e.g. polycystic kidney disease with a transplant) vs. high risk (diabetic with previous myocardial infarction on dialysis) patients even within the same age band. Excluded: Data from centres with less than 20 patients are excluded (Clwyd, Derry, D & Gall, Ulster, Wrexham) Survival in UK RRT patients in 2009
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